Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof

a technology of pathogenic microorganisms and compositions, applied in the directions of antibody medical ingredients, spray delivery, aerosol delivery, etc., can solve the problems of human contact with infected animals or animal products, animal anthrax infection still represents a significant problem, and domestic, agricultural and wild animals are affected by fatal diseases, etc., to reduce the morbidity, mortality, and/or infectivity , the effect of minimizing microbial resistan

Inactive Publication Date: 2006-11-09
NANOBIO CORP
View PDF49 Cites 204 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention provides emulsions that can decrease the infectivity, morbidity, and mortality associated with pathogenic exposure while minimizing microbial resistance, toxicity to the recipient, and deleterious effects to equipment and the environment. The emulsions comprise particles with an average diameter of less than 150 nm. The invention also provides methods of making and using the emulsions, as well as a kit for preparing them. The technical effects of the invention include reducing the average particle size of nanoemulsions, inactivating microorganisms, and preventing infected states caused by microorganisms."

Problems solved by technology

For example, contamination of farmlands with B. anthracis can lead to a fatal disease in domestic, agricultural, and wild animals, as well as in humans in contact with infected animals or animal products.
However, animal anthrax infection still represents a significant problem due to the difficulty of decontaminating land and farms.
While an anthrax vaccine is available and can be used for the prevention of classic anthrax, genetic mixing of different bacterial strains can render it ineffective.
A person infected with an antibiotic resistant strain of bacteria faces serious and potentially life-threatening consequences because antibiotics cannot eliminate the infection.
Pneumococci, which cause pneumonia and meningitis, Salmonella and E. coli which cause diarrhea, and enterococci which cause blood stream, surgical wound, and urinary tract infections can all develop antibiotic resistance resulting in fatal infections.
Moreover, antibiotics are not effective in eliminating or inactivating bacterial spores and viruses.
Disinfectants and biocides, such as sodium hypochlorite, formaldehyde and phenols can be effective against bacterial spores, but are not well suited for decontamination of the environment, equipment, or casualties.
The toxicity of these compounds can result in tissue necrosis and severe pulmonary injury following contact or inhalation of volatile fumes.
Furthermore, the corrosive nature of commonly used disinfectants and biocides renders them unsuitable for decontamination of sensitive equipment.
Viruses are additional pathogens that infect human and animals which currently lack effective means of inactivation.
Current anti-viral compounds and neuraminidase inhibitors are minimally effective and viral resistance is common.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
  • Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
  • Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Comparison of Standard Emulsions and Small pParticle Size Nanoemulsions

[0111] The nanoemulsions are described by the components of the nanoemulsion according to Table 1. Unless otherwise noted, the oil is soybean oil. In the formulations, the detergent is listed first, followed by the volume percentage of the detergent (e.g., W205 refers to 5 vol % of Tween 20). In the formulations, the designation L2 refers to a small particle size nanoemulsion produced by a microfluidizer, while the absence of the L2 designation refers to a standard nanoemulsion (i.e., average particle sizes of 250 nm to about 1 micrometer). The designation L3 refers to nanoemulsions produced using an Avesting high pressure homogenizer.

TABLE 1ComponentSymbolTween 20W20EthanolECetylpyridinium chlorideCEDTAEDTriton X-100XTributyl phosphatePGlycerolGBenzalkonium chlorideBA

[0112] A first nanoemulsion is produced from a mixture containing 548 milliliters of water, 2.24 grams of EDTA, 25 grams of cetylpyridiunium chl...

example 2

Method of Making a Small Particle Size Nanoemulsion

[0115] A standard nanoemulsion (i.e., particles sizes of 250 nm to 5 micrometers) is formed as follows. A mixture of 22 vol % distilled water, 1 wt / vol % cetylpyridinium chloride, 5 vol % Tween 20, 64 vol % soybean oil, and 8 vol % ethanol based on the total volume of the mixture is formed. The nanoemulsion is formed by mixing for 5 minutes at 10,000±500 revolutions per minute with a Silverson L4RT mixer with a standard mixing assembly and a fine emulsion screen. The standard nanoemulsion is denoted as W205EC.

[0116] A small particle size nanoemulsion is formed by passing the W205EC nanoemulsion 4 times through a Microfluidics M-110EH microfluidizer processor using an H210Z (200 μm) chamber downstream of an H230Z (400 μm) chamber. The small particle size nanoemulsion is denoted as W205EC L2.

[0117] After formation, the W205EC and W205EC L2 emulsions are diluted with water for further testing. Particle sizes are determined by Partic...

example 3

Effect of Microfluidizer Chamber Size on the Size of Small Particle Size Nanoemulsion Particles

[0119] A W205G BA2 nanoemulsion is passed through different combinations of microfluidizer chambers as shown in Table 4. The W205G BA2 L2 small particle size nanoemulsion is made with 1 pass with a Silverson L4RT mixer and 4 passes through a microfluidizer. Combinations of chamber having 75, 200, 400 micrometer microchannels are used to determine the relationship between the size of the microchannels and the size of the particles produced.

TABLE 4FirstSecond chamber,ParticleSamplechamber, μmμmsize, nm175100174210075165375200185420075180575400211640075199

[0120] As shown in Table 4, the chamber size utilized in the microfluidizer, when varied between 75 and 400 μm, does not significantly affect the particle size of the emulsions. In all cases, the particle size is less than or equal to about 250 nm.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

Nanoemulsion compositions with low toxicity that demonstrate broad spectrum inactivation of microorganisms or prevention of diseases are described. The nanoemulsions contain an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants. Methods of making nanoemulsions and inactivating pathogenic microorganisms are also provided.

Description

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS [0001] This application is a continuation of co-pending U.S. patent application Ser. No. 11 / 067,626, which is a continuation of U.S. patent application Ser. No. 10 / 860,582, which claims the benefit under 35 USC § 119(e) of U.S. application Ser. No. 60 / 475,633, filed Jun. 4, 2003, incorporated herein by reference in its entirety.FIELD OF THE INVENTION [0002] The present disclosure relates to compositions and methods for decreasing the infectivity, morbidity, and / or rate of mortality associated with a variety of pathogenic microorganisms. BACKGROUND OF THE INVENTION [0003] Pathogenic microorganisms such as bacteria, fungi, viruses, and bacterial spores are responsible for a plethora of human and animal ailments. In addition to vegetatively growing bacteria, bacteria of the Bacillus genus and others form stable spores that resist harsh conditions and extreme temperatures. For example, contamination of farmlands with B. anthracis can lead t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/12A61K39/07A61K39/00A61K39/38A61K9/00A01N25/02A01N25/04A61K9/107A61K31/7048
CPCA01N25/02A01N25/04A61K9/0014A61K9/0034A61K9/0043A61K39/00A61K9/1075A61K31/7048A61K2039/5252C12N7/00C12N2760/16163A61K9/0073A61P31/00A61P31/04A61P31/10A61P31/12A61P31/22
Inventor ANNIS, THEODORE C.BAKER, JAMES R. JR.HAMOUDA, TAREK
Owner NANOBIO CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products